Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Considerations and Statute of Limitations in Massachusetts

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Hazard Awareness

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their broad benefits. This legacy context emphasized the importance of informed consent and the balance between therapeutic efficacy and patient safety. Within this framework, patients and healthcare providers have navigated complex decisions about disease-modifying therapies, including those used for chronic conditions such as multiple sclerosis. The transition from this general health perspective to a more specific occupational exposure concern requires a shift in focus from population-level benefits to individual risk awareness in professional settings. As the conversation moves toward Tysabri exposure and the associated risk of progressive multifocal leukoencephalopathy, a distinct layer of accountability emerges. In the context of mass production environments—such as pharmaceutical manufacturing, clinical administration, or laboratory handling—workers may face repeated or high-level contact with biological agents or drug compounds. This occupational exposure introduces considerations that differ from those of the typical patient. The question of legal recourse, including the statute of limitations for Tysabri-related claims in Massachusetts, becomes relevant when such exposure leads to adverse health outcomes. Thus, the pivot from general health literacy to occupational hazard management underscores the need for clear timelines and professional safeguards in settings where exposure is not incidental but inherent to the role.

Tysabri and PML: Medical Background and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn’s disease (CD) in adults. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the label identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, visual changes, and speech difficulties. These symptoms overlap with those of multiple sclerosis, which can delay diagnosis. In FAERS adverse-event reports, Tysabri is most frequently associated with fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), and balance disorder (5,621 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may be reported by patients, some of which could be early signs of PML.

Mechanism of PML Development and Legal Implications

The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial in MS, but it also impairs immune surveillance against the JC virus. In the setting of reduced T-cell trafficking to the brain, latent JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, have received Tysabri for more than two years, or have a history of immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients in Massachusetts who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Massachusetts, the statute of limitations for personal injury actions generally is three years from the date the injury is discovered or reasonably should have been discovered. For PML, the timeline between exposure to Tysabri and documented harm can be variable. PML may develop months to years after starting therapy, and symptoms may be initially attributed to MS relapse. The diagnosis is confirmed by MRI findings and detection of JCV DNA in cerebrospinal fluid. Given that the boxed warning explicitly states that Tysabri increases the risk of PML and that risk factors include anti-JCV antibodies and treatment duration beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), the adequacy of warnings is a central issue. Patients and their attorneys may examine whether healthcare providers adequately communicated these risks and whether monitoring for PML was conducted as recommended.

Statute of Limitations and Legal Recourse in Massachusetts

The risk narrative for affected patients involves a sequence of events: initiation of Tysabri for MS or Crohn’s disease, continued treatment beyond two years, development of neurological symptoms, diagnostic evaluation for PML, and subsequent disability or death. The label states that physicians should consider whether the expected benefit of Tysabri is sufficient to offset the risk of PML when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For patients who were not informed of this risk or who were not monitored appropriately, legal claims may focus on failure to warn or failure to monitor. The statute of limitations clock typically starts when the patient knows or should know of the injury and its possible cause. Given the latency of PML, this may be later than the date of first exposure. Attorneys should document the date of PML diagnosis, the date of last Tysabri infusion, and any communications about risk from the prescribing physician. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors identified in the prescribing information. Patients in Massachusetts who develop PML should be aware of the statute of limitations for filing claims, which generally runs from discovery of the injury. The adequacy of warnings and monitoring practices are key considerations in any legal evaluation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury actions generally is three years from the date the injury is discovered or reasonably should have been discovered. For PML, the clock typically starts when the patient knows or should know of the injury and its possible cause, which may be later than the date of first Tysabri exposure.

What are the key risk factors for developing PML while on Tysabri?

The prescribing information identifies three risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.